Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

GlobeNewswire September 9, 2019

ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

GlobeNewswire August 12, 2019

ProQR Announces Financial Results for the Second Quarter of 2019

GlobeNewswire August 7, 2019

European Medicines Agency Grants PRIME Access to ProQR's Sepofarsen for Leber's Congenital Amaurosis 10

GlobeNewswire July 29, 2019

European Medicines Agency Grants PRIME Access to ProQR's Sepofarsen for Leber's Congenital Amaurosis 10

Thomson Reuters ONE July 29, 2019

ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July

GlobeNewswire July 2, 2019

ProQR to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 3, 2019

ProQR to Present at the RBC Capital Markets Healthcare Conference

GlobeNewswire May 15, 2019

ProQR Announces Financial Results for the First Quarter of 2019

GlobeNewswire May 8, 2019

ProQR to Present at Three Scientific Conferences in April

GlobeNewswire April 22, 2019

ProQR Announces Annual Meeting of Shareholders

GlobeNewswire April 18, 2019

ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

GlobeNewswire April 18, 2019

ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

GlobeNewswire April 15, 2019

ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

GlobeNewswire January 7, 2019

ProQR to Host R&D Day in New York on January 29

GlobeNewswire January 3, 2019

16 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  January 2, 2019

ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2

GlobeNewswire January 2, 2019

ProQR Therapeutics Added to NASDAQ Biotechnology Index

GlobeNewswire December 24, 2018

ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10

GlobeNewswire December 17, 2018

ProQR Announces Strategic Changes to the Management Team and Key New Hires

GlobeNewswire December 13, 2018